Treatment options for advanced pancreatic neuroendocrine tumors: What is on the horizon?

Edward M. Wolin

Research output: Contribution to journalReview articlepeer-review


Treatment options for patients with advanced or metastatic pancreatic tumors (pNET) have expanded greatly in recent years. These treatments include resection, ablation or embolization of liver metastases and systemic therapy with everolimus or sunitinib and cytotoxic agents. New investigational approaches include the use of inhibitors of multiple downstream effectors in the PI3K/Akt/mTOR pathway, novel antiangiogenics, somatostatin analogues, new tyrosine kinase inhibitors and peptide receptor radionuclide therapy. The treatment horizon for pNET patients may offer improved duration of tumor control and survival and more effective symptom control. 2015

Original languageEnglish (US)
Pages (from-to)39-55
Number of pages17
JournalInternational Journal of Endocrine Oncology
Issue number1
StatePublished - Jan 1 2015
Externally publishedYes


  • Clinical trials
  • Emerging and novel agents
  • Pancreatic neuroendocrine tumors
  • PNET
  • Survival
  • Symptoms

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Cancer Research


Dive into the research topics of 'Treatment options for advanced pancreatic neuroendocrine tumors: What is on the horizon?'. Together they form a unique fingerprint.

Cite this